2D Versus 3D Radical Laparoscopic Hysterectomy for Cervical Cancer: a Prospective Randomized Trial
Launched by CATHOLIC UNIVERSITY OF THE SACRED HEART · Dec 16, 2014
Trial Information
Current as of May 03, 2025
Completed
Keywords
ClinConnect Summary
Radical abdominal hysterectomy (RAH) with pelvic lymphadenectomy is the standard surgical treatment for early stage cervical carcinoma FIGO stages IA2-IB1-IIA\<2cm. Since the early 90's laparoscopic radical hysterectomy with pelvic lymphadenectomy (LRH) has been suggested as surgical approach for the treatment of cervical cancer. In the recent years, many institutions have begun to consider it an attractive technique and to study its feasibility and safety. Most of these studies have shown that LRH is relatively more time-consuming than standard laparotomy and ranges from 90 to 420 minutes ...
Gender
FEMALE
Eligibility criteria
- • Age ≤ 75 years
- • Patient's informed consent
- • American Society of Anesthesiologists: \< class III or IV
- • No actual pregnancies or P.I.D.
- • No previous major abdominal surgical procedures
- • Early stage cervical cancer (FIGO stages IA2-IB1-IIA\<2cm) and advanced stage cervical cancer (FIGO stages IB2-IIA\>2cm-IIB) submitted to NACT with complete clinical response
- • No previous radiotherapy on the pelvic field
- • No uterine size larger than conform 10 weeks gestation
About Catholic University Of The Sacred Heart
The Catholic University of the Sacred Heart is a prestigious academic institution in Italy, renowned for its commitment to advancing medical research and education. With a strong emphasis on ethical standards and community well-being, the university actively engages in clinical trials that contribute to innovative healthcare solutions. Its multidisciplinary approach leverages expertise from various fields, fostering collaborations that enhance the quality and impact of research. The university is dedicated to improving patient outcomes through rigorous science and compassionate care, aligning with its mission to serve the greater good.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Rome, , Italy
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials